- Processing Solutions
- White Papers
- Tech Portals
- Buyer's Guide
TRENTON, N.J. — Outside advisers to the U.S. Food and Drug Administration (FDA) voted Thursday to recommend that the agency approve a new anticlotting drug for use in millions more patients, Bloomberg reported.
Johnson & Johnson and partner Bayer Healthcare of Germany, which jointly developed the drug, Xarelto, are seeking U.S. approval for preventing strokes in patients with a common irregular heart rhythm known as atrial fibrillation.
The drug is already approved to prevent clots in people getting knee and hip replacements.The FDA is expected to make a final decision by early November.